

Drug resistance interpretation: PR

PI Major Mutations:

PI Accessory Mutations:

PR Other Mutations:

None

None

L10V 99%
seen=2,060 • I13V 99%
seen=2,363 • G16E 100%
seen=2,319 • E35D 100%
seen=3,071 • M36I 99%
seen=3,071 • N37D 99%
seen=3,071 • R41K 99%
seen=3,218 • R57K 99%
seen=2,908 • D60E 99%
seen=2,907 • H69K 79%
seen=2,787 • K70KR 91,79%
seen=2,787 • L89M 100%
seen=3,903 • T91V 100%
seen=2,641

Protease Inhibitors

atazanavir/r (ATV/r)

Susceptible

darunavir/r (DRV/r)

Susceptible

fosamprenavir/r (FPV/r)

Susceptible

indinavir/r (IDV/r)

Susceptible

lopinavir/r (LPV/r)

Susceptible

nelfinavir (NFV)

Susceptible

saquinavir/r (SQV/r)

Susceptible

tipranavir/r (TPV/r)

Susceptible

PR comments

Other

- L10(I)V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.

Mutation scoring: PR

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations:

NNRTI Mutations:

RT Other Mutations:

M184V 99%
seen=9,625

None

E6N 99%
seen=2,294 • K11Q 99%
seen=3,033 • V35T 100%
seen=3,400 • T39K 99%
seen=3,449 • V60I 100%
seen=3,226 • D121Y 100%
seen=3,443 • K122E 99%
seen=3,400 • T165I 99%
seen=3,965 • K173A 100%
seen=4,817 • Q174R 99%
seen=3,842 • D177E 99%
seen=4,630 • I178L 100%
seen=4,630 • V179I 99%
seen=4,630 • T200V 100%
seen=7,747 • Q207A 100%
seen=4,626 • F214L 100%
seen=3,841 • V245Q 100%
seen=4,630 • E248N 100%
seen=3,842 • A272P 100%
seen=4,630 • A554N 100%
seen=2,027 • V559I 100%
seen=2,796

Nucleoside Reverse Transcriptase Inhibitors

abacavir (ABC)

Low-Level Resistance

zidovudine (AZT)

Susceptible

stavudine (D4T)

Susceptible

didanosine (DDI)

Potential Low-Level Resistance

emtricitabine (FTC)

High-Level Resistance

lamivudine (3TC)

High-Level Resistance

tenofovir (TDF)

Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors

doravirine (DOR)

Susceptible

efavirenz (EFV)

Susceptible

etravirine (ETR)

Susceptible

nevirapine (NVP)

Susceptible

rilpivirine (RPV)

Susceptible

RT comments

NRTI

- M184V(I) cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). M184V(I) are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.

Other

- V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

Drug resistance mutation scores of NRTI:

Download CSV

Rule	ABC ⇅	AZT ⇅	D4T ⇅	DDI ⇅	FTC ⇅	3TC ⇅	TDF ⇅
M184V	15	-10	-10	10	60	60	-10

No drug resistance mutations were found for NNRTI.

Drug resistance interpretation: IN

HIVDB 9.5.1 (2023-11-05)

INSTI Major Mutations:

INSTI Accessory Mutations:

IN Other Mutations:

None

None

S17N 100%
seen=452 • M30ML 91,107%
seen=700 • I72V 100%
seen=373 • K111R 99%
seen=318 • T112A 100%
seen=318 • I113V 99%
seen=326 • T124A 99%
seen=400 • T125A 100%
seen=400 • G193E 100%
seen=1,060 • V203I 100%
seen=312 • E212EA 9,79%
seen=106 • I,79%
seen=106 • L,24%

Integrase Strand Transfer Inhibitors

bictegravir (BIC)

Susceptible

cabotegravir (CAB)

Susceptible

dolutegravir (DTG)

Susceptible

elvitegravir (EVG)

Susceptible

raltegravir (RAL)

Susceptible

Mutation scoring: IN

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for INSTI.